Evidence map›Paper›PMID 38993742›Full record

ReviewJournal of hematology2024

Sickle Cell Screening in Adults: A Current Review of Point-of-Care Testing.

Sebastian R Mendez-Marti, Chad Zik, Sheinei Alan, Hongkun Wang, William B Ershler

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sebastian R Mendez-MartiAdult Sickle Cell Center, Inova Schar Cancer Institute, Inova Fairfax Medical Campus, Fairfax, VA, USA.
Chad ZikAdult Sickle Cell Center, Inova Schar Cancer Institute, Inova Fairfax Medical Campus, Fairfax, VA, USA.
Sheinei AlanAdult Sickle Cell Center, Inova Schar Cancer Institute, Inova Fairfax Medical Campus, Fairfax, VA, USA.
Hongkun WangBiostatics, Bioinformatics and Biomathematics Department, Georgetown University, Washington, DC, USA.
William B ErshlerAdult Sickle Cell Center, Inova Schar Cancer Institute, Inova Fairfax Medical Campus, Fairfax, VA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In adults, the sickle cell solubility test (SCST) is the most common screening test to determine the presence of hemoglobin S (HbS) within a blood sample. The assay is inexpensive, rapid, highly sensitive and specific. However, the SCST cannot accurately quantify the level of HbS in a test sample and requires confirmatory testing to distinguish between sickle trait and sickle cell disease. Despite these limitations, it remains the standard screening tool for HbS in a variety of settings such as screening in the US military or by the National Collegiate Athletic Association. With an increased awareness of the importance of screening for sickle cell in adults, we herein describe the current sensitivity, specificity, positive predictive value, and negative predictive value of this test. We also review overall clinical utility of this laboratory measure and briefly discuss new point-of-care techniques designed to overcome the SCST's shortcomings.

Indexed as

Point-of-care screeningSickle cell diseaseSickle cell screeningSickle cell solubility testSickle cell trait

Identifiers

PMID38993742
PMCPMC11236353

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.